Scarica l'app Stockscreener
4.595
3.67%
-0.175
Dopo l'orario di chiusura:
4.69
0.095
+2.07%
Precedente Chiudi:
$4.77
Aprire:
$4.87
Volume 24 ore:
3.84M
Relative Volume:
1.00
Capitalizzazione di mercato:
$476.00M
Reddito:
-
Utile/perdita netta:
$-36.95M
Rapporto P/E:
-5.4702
EPS:
-0.84
Flusso di cassa netto:
$-33.46M
1 W Prestazione:
-11.97%
1M Prestazione:
+45.87%
6M Prestazione:
+16.92%
1 anno Prestazione:
+76.05%
Intervallo 1D:
$4.45
$5.01
Intervallo di 1 settimana:
$4.45
$6.00
Portata 52W:
$1.61
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Nome
Larimar Therapeutics Inc
Settore
Industria
Telefono
844-511-9056
Indirizzo
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
4.595 | 476.00M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-29 | Iniziato | Truist | Buy |
| 2024-10-16 | Iniziato | Oppenheimer | Outperform |
| 2024-10-03 | Iniziato | Wedbush | Outperform |
| 2024-10-02 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-03 | Iniziato | Leerink Partners | Outperform |
| 2023-11-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-19 | Iniziato | Guggenheim | Buy |
| 2022-02-15 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-02-01 | Iniziato | William Blair | Outperform |
Mostra tutto
Larimar Therapeutics Inc Borsa (LRMR) Ultime notizie
Larimar Advances Nomlabofusp Toward 2026 BLA Submission - The Globe and Mail
LRMR: Nomlabofusp shows strong efficacy and regulatory momentum for Friedreich's ataxia, with BLA submission planned for 2026 - TradingView
Larimar Therapeutics posts updated corporate deck outlining nomlabofusp BLA plan, Q2 2026 topline and cash runway - TradingView
Larimar Therapeutics (LRMR) advances nomlabofusp toward 2026 BLA and Phase 3 - Stock Titan
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
ETF Watch: Is Larimar Therapeutics Inc. stock a good choice for value investorsMarket Movers & Verified Swing Trading Watchlists - Naître et grandir
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? - TradingView
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March - Sahm
Larimar surges on FDA breakthrough status for lead asset - MSN
Larimar Therapeutics Launches $75 Million Public Offering of Common Stock and Pre-Funded Warrants - Global Legal Chronicle
Larimar Therapeutics price target raised to $12 from $11 at Wedbush - finance.yahoo.com
FDA Grants Breakthrough Status to Larimar’s Nomlabofusp - MyChesCo
Wedbush Maintains Outperform on Larimar Therapeutics, Inc. (LRMR) March 2026 - Meyka
LRMR Stock Rating Maintained Outperform by Wedbush, Price Target - GuruFocus
Wedbush raises Larimar Therapeutics stock price target to $12 By Investing.com - Investing.com Canada
Wedbush raises Larimar Therapeutics stock price target to $12 - Investing.com
Larimar Therapeutics (NASDAQ:LRMR) Price Target Raised to $12.00 - MarketBeat
Larimar Therapeutics Stock (LRMR) Opinions on Public Offering and Insider Purchases - Quiver Quantitative
LRMR News & Events - Intellectia AI
Larimar Therapeutics: Deerfield entities buy $25m in stock By Investing.com - Investing.com South Africa
Larimar Therapeutics: Deerfield entities buy $25m in stock - Investing.com Nigeria
James Flynn Acquires 5,000,000 Shares of Larimar Therapeutics (NASDAQ:LRMR) Stock - MarketBeat
Insider Buying: Frank Thomas Acquires Additional Shares of Larim - GuruFocus
Wedbush Adjusts Larimar Therapeutics PT to $12 From $11, Maintains Outperform Rating - marketscreener.com
Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed? - Yahoo Finance
Larimar Therapeutics Announces Upsized Public Equity Offering - TipRanks
Larimar Therapeutics Prices $5.00 Public Offering, Nets ~$107.6 Million as Option Is Exercised - TradingView
Larimar Therapeutics stock dips after pricing $100M share offering - MSN
Larimar Therapeutics prices $100M stock offering at $5 per share - Investing.com Australia
Larimar Therapeutics Prices Upsized $100 Million Public Stock Offering - marketscreener.com
Larimar Therapeutics stock falls 8% on upsized $100 million offering By Investing.com - Investing.com Canada
What is Lifesci Capital's Estimate for LRMR FY2025 Earnings? - MarketBeat
Larimar Therapeutics Prices Upsized 20 Mln Public Offering At $5.00 Per Share, Stock Down - Nasdaq
Larimar Therapeutics (LRMR) Upsizes Public Offering to Raise $10 - GuruFocus
Larimar Therapeutics announces pricing of upsized $100 million underwritten public offering - marketscreener.com
Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy - Asianet Newsable
LRMR Expands Offering to $100 Million - GuruFocus
Larimar Therapeutics Prices Upsized Public Offering - Intellectia AI
Larimar Therapeutics, Inc. Prices Upsized Public Offering of 20 Million Shares at $5.00 Each - Quiver Quantitative
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering - Stock Titan
Larimar Therapeutics launches $75M public stock offering By Investing.com - Investing.com Australia
Larimar Therapeutics Announces Pricing Of Upsized $100 Million Underwritten Public Offering - TradingView
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering - Benzinga
Laminar Therapeutics stock is popping today: What's going on? - MSN
Larimar Therapeutics launches proposed $75 million public offering - MSN
Press Release: Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering - 富途牛牛
Larimar Therapeutics launches $75M public stock offering - Investing.com
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering - Bitget
Rare-disease biotech Larimar seeks $75M to fund key drug - Stock Titan
Larimar Therapeutics Inc Azioni (LRMR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):